1199 related articles for article (PubMed ID: 8551248)
1. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
3. Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
Cancer Immunol Immunother; 1998 May; 46(3):128-36. PubMed ID: 9625536
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.
Kato M; Nakamura Y; Suda T; Ozawa Y; Inui N; Seo N; Nagata T; Koide Y; Kalinski P; Nakamura H; Chida K
Cancer Immunol Immunother; 2011 Jul; 60(7):1029-38. PubMed ID: 21519830
[TBL] [Abstract][Full Text] [Related]
7. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M
Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011
[TBL] [Abstract][Full Text] [Related]
9. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.
Fenton RG; Keller CJ; Hanna N; Taub DD
J Natl Cancer Inst; 1995 Dec; 87(24):1853-61. PubMed ID: 7494229
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
11. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
Fields RC; Shimizu K; Mulé JJ
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9482-7. PubMed ID: 9689106
[TBL] [Abstract][Full Text] [Related]
12. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation.
Murphy EE; Terres G; Macatonia SE; Hsieh CS; Mattson J; Lanier L; Wysocka M; Trinchieri G; Murphy K; O'Garra A
J Exp Med; 1994 Jul; 180(1):223-31. PubMed ID: 7516409
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.
Gao J; Luo SM; Peng ML; Deng T
J Cancer Res Clin Oncol; 2012 Jun; 138(6):917-26. PubMed ID: 22327301
[TBL] [Abstract][Full Text] [Related]
14. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.
Hermans IF; Daish A; Moroni-Rawson P; Ronchese F
Cancer Immunol Immunother; 1997 Aug; 44(6):341-7. PubMed ID: 9298937
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
16. Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.
Ioannou K; Derhovanessian E; Tsakiri E; Samara P; Kalbacher H; Voelter W; Trougakos IP; Pawelec G; Tsitsilonis OE
BMC Immunol; 2013 Sep; 14():43. PubMed ID: 24053720
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen-pulsed CD8α(+) dendritic cells induce T cell-mediated graft-versus-tumor effect in vitro.
Na N; Chen K; Zhang J; He S; Fu Q; Zhu B; Cao K; Xu L
J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):728-734. PubMed ID: 22173490
[TBL] [Abstract][Full Text] [Related]
18. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.
Tian S; Liu Z; Donahue C; Falo LD; You Z
Mol Ther; 2012 Feb; 20(2):432-42. PubMed ID: 21934655
[TBL] [Abstract][Full Text] [Related]
19. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.
Fujii S; Liu K; Smith C; Bonito AJ; Steinman RM
J Exp Med; 2004 Jun; 199(12):1607-18. PubMed ID: 15197224
[TBL] [Abstract][Full Text] [Related]
20. Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.
Patidar A; Selvaraj S; Chauhan P; Guzman CA; Ebensen T; Sarkar A; Chattopadhyay D; Saha B
Clin Exp Immunol; 2020 Sep; 201(3):279-288. PubMed ID: 32443171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
